Leptospirosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:509A27.8A27.9A27.0
Who is this for?
Show terms as
5Active trials31Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Leptospirosis is an infectious disease caused by pathogenic spirochete bacteria of the genus Leptospira. It is a zoonotic illness, meaning it is transmitted from animals to humans, typically through contact with water, soil, or food contaminated with the urine of infected animals such as rodents, dogs, cattle, and pigs. The bacteria can enter the body through cuts or abrasions in the skin, through mucous membranes (eyes, nose, mouth), or through ingestion of contaminated water. Leptospirosis is also known as Weil disease (in its severe form), canicola fever, swamp fever, mud fever, or hemorrhagic jaundice. The disease affects multiple body systems and has a wide clinical spectrum ranging from mild, self-limiting febrile illness to severe, life-threatening multiorgan dysfunction. Common symptoms include high fever, severe headache, muscle pain (particularly in the calves and lower back), chills, conjunctival suffusion (redness of the eyes without discharge), nausea, vomiting, diarrhea, and skin rash. The illness typically presents in two phases: an initial acute septicemic phase lasting about a week, followed by an immune phase. In severe cases (Weil disease, corresponding to ICD-10 code A27.0), patients may develop jaundice, renal failure, hemorrhagic manifestations, pulmonary hemorrhage, meningitis, and cardiovascular collapse, which can be fatal if untreated. Treatment involves antibiotic therapy, with doxycycline and penicillin being the most commonly used agents for mild and severe cases, respectively. Intravenous penicillin G or ceftriaxone is recommended for severe leptospirosis. Supportive care, including fluid management, dialysis for renal failure, and mechanical ventilation for pulmonary complications, may be necessary in severe cases. Early diagnosis and prompt antibiotic treatment significantly improve outcomes. Doxycycline may also be used as prophylaxis in high-risk exposure settings. Leptospirosis is most prevalent in tropical and subtropical regions, particularly during rainy seasons and flooding events, and is considered one of the most widespread zoonotic diseases globally.

Clinical phenotype terms— hover any for plain English:

HyperproteinemiaHP:0002152Elevated serum transaminases during infectionsHP:0008150Conjunctival hyperemiaHP:0030953Morphological central nervous system abnormalityHP:0002011
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Jun 2025Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI

Institut Pasteur — NA

TrialNOT YET RECRUITING
Oct 2024Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

University Hospital Center of Martinique — PHASE4

TrialNOT YET RECRUITING
Apr 2024Preventive Strategies for Early and Late Complications of Leptospirosis

National Kidney and Transplant Institute, Philippines — PHASE2

TrialRECRUITING
Jul 2022Chronic Post-leptospirosis Manifestations in Reunion

Centre Hospitalier Universitaire de la Réunion — NA

TrialRECRUITING
Jan 2021Cohort of Hospitalized Patients Suspected of Leptospirosis

Institut National de la Santé Et de la Recherche Médicale, France — NA

TrialACTIVE NOT RECRUITING
Mar 2020Leptospirosis Registry - LeptoScope

University of Cologne

TrialRECRUITING
Oct 2019Leptospirosis Care Bundle Study

Chulalongkorn University — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Leptospirosis.

5 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

5 recruitingView all trials with filters →
Phase 21 trial
Preventive Strategies for Early and Late Complications of Leptospirosis
Phase 2
Actively Recruiting
PI: Romina A Danguilan, MD (National Kidney and Transplant Institute, Philippi) · Sites: Manila, National Capital Region; Manila, National Capital Region +1 more · Age: 1860 yrs
N/A3 trials
Chronic Post-leptospirosis Manifestations in Reunion
N/A
Actively Recruiting
· Sites: Saint-Paul; Saint-Pierre +2 more
Cohort of Hospitalized Patients Suspected of Leptospirosis
N/A
Active
PI: Loïc RAFFRAY, MD, PhD (CHU Reunion, INSERM, CNRS, IRD UMR PIMIT) · Sites: Saint-Benoît, Reunion; Saint-Denis, Reunion +2 more
Leptospirosis Care Bundle Study
N/A
Actively Recruiting
· Sites: Bangkok, Bangkok · Age: 1899 yrs
Other1 trial
Leptospirosis Registry - LeptoScope
Actively Recruiting
PI: Volker Burst, MD (University Hospital of Cologne) · Sites: Cologne, North Rhine-Westphalia

Specialists

Showing 25 of 31View all specialists →
LP
Loïc RAFFRAY, MD, PhD
Specialist
PI on 1 active trial
MM
Maryse Beder, MD
Specialist
PI on 1 active trial
SM
Simonetta Viviani, MD
Specialist
PI on 1 active trial
JP
Jean Reignier, MD, PhD
Specialist
PI on 1 active trial
SS
Simone Schuller
Specialist
1 Leptospirosis publication
TF
Thierry Francey
Specialist
1 Leptospirosis publication
JS
Jane E Sykes
Specialist
1 Leptospirosis publication
CM
Claudia Munoz-Zanzi
Specialist
2 Leptospirosis publications
AD
Anou Dreyfus
Specialist
2 Leptospirosis publications
SR
Senaka Rajapakse
Specialist
2 Leptospirosis publications
CR
Chaturaka Rodrigo
Specialist
1 Leptospirosis publication
PP
Pavlo Petakh
Specialist
1 Leptospirosis publication
PB
Payam Behzadi
Specialist
1 Leptospirosis publication
VO
Valentyn Oksenych
Specialist
1 Leptospirosis publication
OK
Oleksandr Kamyshnyi
Specialist
1 Leptospirosis publication
NF
Narmada Fernando
Specialist
1 Leptospirosis publication
GM
George E Moore
Specialist
1 Leptospirosis publication
LC
Larry D Cowgill
Specialist
1 Leptospirosis publication
RM
Romina A Danguilan, MD
Specialist
PI on 1 active trial
MM
Michael Osthoff, PD Dr. med.
Specialist
PI on 5 active trials
FM
Felix Köhler, MD
Specialist
PI on 1 active trial
CP
Claude Flamand, Ph.D.
Specialist
PI on 1 active trial
FP
François Chappuis, MD, PhD
Specialist
PI on 1 active trial
RS
Robyn A Stoddard
Specialist
1 Leptospirosis publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Leptospirosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open LeptospirosisForum →

No community posts yet. Be the first to share your experience with Leptospirosis.

Start the conversation →

Latest news about Leptospirosis

Disease timeline:

New recruiting trial: Chronic Post-leptospirosis Manifestations in Reunion

A new clinical trial is recruiting patients for Leptospirosis

New recruiting trial: Preventive Strategies for Early and Late Complications of Leptospirosis

A new clinical trial is recruiting patients for Leptospirosis

New recruiting trial: Leptospirosis Care Bundle Study

A new clinical trial is recruiting patients for Leptospirosis

New recruiting trial: Leptospirosis Registry - LeptoScope

A new clinical trial is recruiting patients for Leptospirosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Leptospirosis

What is Leptospirosis?

Leptospirosis is an infectious disease caused by pathogenic spirochete bacteria of the genus Leptospira. It is a zoonotic illness, meaning it is transmitted from animals to humans, typically through contact with water, soil, or food contaminated with the urine of infected animals such as rodents, dogs, cattle, and pigs. The bacteria can enter the body through cuts or abrasions in the skin, through mucous membranes (eyes, nose, mouth), or through ingestion of contaminated water. Leptospirosis is also known as Weil disease (in its severe form), canicola fever, swamp fever, mud fever, or hemorrha

Are there clinical trials for Leptospirosis?

Yes — 5 recruiting clinical trials are currently listed for Leptospirosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Leptospirosis?

25 specialists and care centers treating Leptospirosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.